Pharmacogenetic Testing Among Home Health Patients

Status Completed

Clinical Trial Summary

Patients meeting eligibility criteria will be randomized into two groups, one receiving pharmacogenetic testing and the other not receiving pharmacogenetic testing. In this open-label trial, a pharmacist will make medication therapy recommendations using YouScript® Personalized Prescribing System for patients who receive genetic testing and standard drug information resources per usual for patients who do not undergo pharmacogenetic testing.

Clinical Trial Description

Both groups will be followed for 60 days. The number of re-hospitalizations and emergency department (ED) visits will be recorded as well as time to first re-hospitalization and time to first ED visit. Select Outcome and Assessment Information Set (OASIS) metrics (e.g. M1034, M1242, M1710, M1720, M1745, M2110) and Patient Health Questionnaire (PHQ)-2 will be evaluated and documented at time of admission to home health, at 30 days, and at 60 days for improvement in overall status, pain, confusion, anxiety, depression, disruptive behavior, and the need for assistance with activities of daily living (ADLs) and instrumental activities of daily living (IADLs). The number of falls will be collected as well as the proportion of YouScript® recommendations accepted by study pharmacist and passed on to clinicians and the proportion of recommendations accepted by clinicians. ;

Study Design

Related Conditions & MeSH terms

Adverse Drug Events
Adverse Drug Reactions
Cytochrome P450 CYP2C19 Enzyme Deficiency
Cytochrome P450 CYP2C9 Enzyme Deficiency
Cytochrome P450 CYP2D6 Enzyme Deficiency
Cytochrome P450 CYP3A Enzyme Deficiency
Cytochrome P450 Enzyme Deficiency
Drug Interaction Potentiation
Drug Metabolism, Poor, CYP2C19-RELATED
Drug Metabolism, Poor, CYP2D6-RELATED
Drug-Related Side Effects and Adverse Reactions
Poor Metabolizer Due to Cytochrome p450 CYP2C19 Variant
Poor Metabolizer Due to Cytochrome P450 CYP2C9 Variant
Poor Metabolizer Due to Cytochrome P450 CYP2D6 Variant

Clinical Trial Details

NCT number	NCT02378220
Study type	Interventional
Source	Genelex Corporation
Contact
Status	Completed
Phase	N/A
Start date	March 2015
Completion date	March 2016

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03789032` - Study to Evaluate the Effect of Rabeprazole on the Pharmacokinetics of Vadadustat	Phase 1
Completed	`NCT03706222` - Drug-Drug Interactions of Grazoprevir/Elbasvir in Taiwan
Completed	`NCT02191358` - YouScript IMPACT Registry	N/A
Completed	`NCT02485028` - Pharmacokinetic Interaction Study of Dapoxetine 30mg and Mirodenafil 50mg	Phase 1
Completed	`NCT01896557` - Ranitidin Versus Omeprazole in Patients Taking Clopidogrel	Phase 4
Completed	`NCT03011463` - Pharmacokinetic Interaction Between Trospium With an Inhibitor of OCT1 and of P-gp in Subjects Genotyped for OCT1	Phase 1
Completed	`NCT02485041` - Pharmacokinetic Interaction Study of Dapoxetine 30mg and Mirodenafil 100mg	Phase 1
Completed	`NCT01477411` - A Drug-Drug Interaction Study of Digoxin and PA21	Phase 1
Completed	`NCT01477424` - A Drug-Drug Interaction Study of Warfarin and PA21	Phase 1
Completed	`NCT05558150` - Study to Evaluate Pharmacokinetic Drug Interactions and Safety of Ilaprazole and Aceclofenac	Phase 1
Completed	`NCT03493698` - A Fixed-Sequence, Drug-Drug Interaction Study Between Multiple Oral Doses of Inarigivir Soproxil and a Single Oral Dose of Midazolam in Healthy Subjects	Phase 1
Completed	`NCT03126578` - Open-label, Single Center, Non-randomized, Fixed Sequence Phase 1 Drug-drug Interaction Study With LEO 32731 and Midazolam	Phase 1
Completed	`NCT01369186` - Drug Drug Interactions of Aspirin and P2Y12-inhibitors	Phase 4
Completed	`NCT01324752` - A Drug-Drug Interaction Study of Losartan and PA21	Phase 1
Completed	`NCT02500667` - A Drug-Drug Interaction Study of N91115 +/- Rifampin in Healthy Adult Subjects	Phase 1
Completed	`NCT03801733` - Drug-Drug Interaction Study of Vadadustat With Rosuvastatin, Sulfasalazine, Pravastatin, Atorvastatin and Simvastatin	Phase 1
Completed	`NCT03801746` - Drug-Drug Interaction Study of Vadadustat With Cyclosporine, Probenecid and Rifampin	Phase 1
Completed	`NCT03801759` - Drug-Drug Interaction Study of Vadadustat With Digoxin, Adefovir and Furosemide	Phase 1
Completed	`NCT01736371` - Analysis of Cisatracurium Consumption in Balanced Anesthesia With 1% Sevoflurane, and With Only Sevoflurane, Using a Closed-loop Computer Controlled System Infusion.	N/A
Completed	`NCT05237297` - Study to Evaluate Pharmacokinetic Drug Interactions and Safety of Naproxen, Aceclofenac, Celecoxib and Ilaprazole	Phase 1